![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-m.jpg)
![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-d.jpg)
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 29, 2019
SAVARA INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-32157 | 84-1318182 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
6836 Bee Cave Road, Building III, Suite 200
Austin, TX 78746
(Address of principal executive offices, including zip code)
(512) 961-1891
(Registrants telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 4.01. | Changes in Registrants Certifying Accountant. |
(a) Dismissal of Independent Registered Public Accounting Firm.
On March 29, 2019, Savara Inc. (the Company) dismissed PricewaterhouseCoopers LLP (PWC), which was serving as the Companys independent registered public accounting firm. The decision to change accountants was approved by the audit committee of the Companys board of directors (the Audit Committee).
The reports of PWC on the Companys consolidated financial statements for the years ended December 31, 2018 and December 31, 2017 did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the years ended December 31, 2018 and December 31, 2017, and the subsequent interim period through March 29, 2019, there were no: (1) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with PWC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement if not resolved to the satisfaction of PWC would have caused PWC to make reference thereto in its reports on the consolidated financial statements for such years, or (2) reportable events (as described in Item 304(a)(1)(v) of Regulation S-K).
The Company delivered a copy of this Current Report on Form 8-K to PWC on March 29, 2019 and requested a letter addressed to the SEC stating whether or not it agrees with the statements made in response to this Item 4.01 and, if not, stating the respects in which it does not agree. PWC responded with a letter dated April 3, 2019, stating its agreement with such statements, a copy of which is filed herewith as Exhibit 16.1.
(b) Engagement of New Independent Registered Public Accounting Firm.
On March 29, 2019, the Audit Committee approved the engagement of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019, subject to completion of its standard client acceptance procedures.
During the years ended December 31, 2018 and December 31, 2017, and in the subsequent interim period through March 29, 2019, neither the Company nor anyone acting on its behalf consulted with Ernst & Young LLP regarding any of the matters or events set forth in Item 304(a)(2) of Regulation S-K.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. | Description | |
16.1 | Letter from PricewaterhouseCoopers LLP to the Securities and Exchange Commission, dated April 3, 2019 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 3, 2019 | SAVARA INC. | |||||
a Delaware corporation | ||||||
By: | /s/ Dave Lowrance | |||||
Dave Lowrance | ||||||
Chief Financial Officer |
Exhibit 16.1
April 3, 2019
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Savara Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01. of Form 8-K of Savara Inc. dated March 29, 2019. We agree with the statements concerning our Firm contained therein.
Very truly yours, |
/s/ PricewaterhouseCoopers LLP |
Austin, Texas |